Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Domingo-Domenech, EvaHorwitz, StevenPro, BarbaraIllidge, TimTrumper, LorenzIyer, SwamiAdvani, RanjanaBartlett, Nancy L.Christensen, Jacob HaaberKim, Won SeogFeldman, TatyanaChoi, IlseungGritti, GiuseppeBelada, DavidShustov, AndreiIllés, ÁrpádZinzani, Pier LuigiHüttmann, AndreasTrneny, MarekLe Gouill, StevenJagadeesh, DeepaFriedberg, Jonathan W.Little, MeredithDong, CassieFanale, MichelleFenton, KeenanSavage, Kerry J.2025-08-072025-08-072025Blood Cancer Journal. -15 : 1 (2025), p. 1-5. -(cikkazonosító)129. -Blood Cancer J. - 2044-53852044-5385https://hdl.handle.net/2437/396645Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM131823OrvostudományokKlinikai orvostudományokszerzőhttp://dx.doi.org/10.1038/s41408-025-01329-22025-08-07001542583400001